Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
1(50.0%)
Phase 1
1(50.0%)
2Total
N/A(1)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT01402232Unknown

REduction of rIsk for Contrast Induced Nephropathy

Role: collaborator

NCT02643823Phase 1Unknown

Human Umbilical Cord-Mesenchymal Stem Cells for Rheumatoid Arthritis

Role: collaborator

NCT02289586Not ApplicableUnknown

Interventional Bronchoscopy Under Noninvasive Ventilation

Role: lead

All 3 trials loaded